Tourmaline Bio Inc. Total Liabilities
Tourmaline Bio Inc. total liabilities. Based on the latest financial reports, Tourmaline Bio Inc. (TRML) has total liabilities worth $10.10 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Tourmaline Bio Inc.'s assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tourmaline Bio Inc. (2019–2024)
Total liabilities of Tourmaline Bio Inc. from 2019 to 2024. This chart illustrates how Tourmaline Bio Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore Tourmaline Bio Inc. long-term investment intensity to see how much of total assets are deployed in long-term investments.
Tourmaline Bio Inc. Competitors by Total Liabilities
The table below lists competitors of Tourmaline Bio Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sunstone Development Co Ltd
SHG:603612
|
China | CN¥13.49 Billion |
|
Fujian Kuncai Material Tech
SHG:603826
|
China | CN¥3.01 Billion |
|
Treehouse Foods Inc
NYSE:THS
|
USA | $2.51 Billion |
|
Biotage AB
ST:BIOT
|
Sweden | Skr862.00 Million |
|
West China Cement Limited
F:WFG1
|
Germany | €21.32 Billion |
|
Sarawak Oil Palms Bhd
KLSE:5126
|
Malaysia | RM1.51 Billion |
|
Orezone Gold Corporation
AU:ORE
|
Australia | AU$742.92 Million |
|
Silicon2 Co. Ltd.
KQ:257720
|
Korea | ₩275.56 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Tourmaline Bio Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Tourmaline Bio Inc..
Liquidity & Leverage Metrics
Tourmaline Bio Inc. Total Liabilities Ratios Explained
Tourmaline Bio Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 24.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tourmaline Bio Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tourmaline Bio Inc. (2019–2024)
The table below shows the annual total liabilities of Tourmaline Bio Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.95 Million | +70.36% |
| 2023-12-31 | $5.25 Million | -81.78% |
| 2022-12-31 | $28.83 Million | +234.73% |
| 2021-12-31 | $8.61 Million | +80.45% |
| 2020-12-31 | $4.77 Million | +102.76% |
| 2019-12-31 | $2.35 Million | -- |
About Tourmaline Bio Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline c… Read more